## Jiaming Lai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10223147/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2115-2125.	2.5	55
2	Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2022, 28, 1896-1910.	7.0	24
3	Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. Cancer Immunology Research, 2022, 10, 728-744.	3.4	27
4	Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2743-2757.	2.5	6
5	Threeâ€day postoperative antibiotics reduces postâ€hepatectomy infection rate in hepatitis B virusâ€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2531-2539.	2.8	3
6	N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Molecular Cell, 2021, 81, 3339-3355.e8.	9.7	146
7	Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A. Annals of Surgical Oncology, 2020, 27, 3740-3753.	1.5	2
8	Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2220-2228.	2.8	4
9	IDDF2020-ABS-0064â€Three-Day Postoperative Antimicrobial Prophylaxis Can Reduce the Incidence of Postoperative Infection in Primary Hepatocellular Carcinoma: A Multicenter Retrospective Study. , 2020, , .		0
10	Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma. Translational Cancer Research, 2020, 9, 6768-6779.	1.0	4
11	Pancreatic head cancer involving variant common hepatic artery with situs inversus totalis. ANZ Journal of Surgery, 2018, 88, 506-508.	0.7	8
12	The optimal choice for pancreatic anastomosis after pancreaticoduodenectomy: A network meta-analysis of randomized control trials. International Journal of Surgery, 2018, 57, 111-116.	2.7	43
13	WAVE3 promotes proliferation, migration and invasion via the AKT pathway in pancreatic cancer. International Journal of Oncology, 2018, 53, 672-684.	3.3	6
14	Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. PLoS ONE, 2018, 13, e0191095.	2.5	11
15	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	9.4	637
16	Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget, 2016, 7, 17220-17229.	1.8	113
17	Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Scientific Reports, 2016, 6, 22976.	3.3	27
18	WAVE3 Induces EMT and Promotes Migration and Invasion in Intrahepatic Cholangiocarcinoma. Digestive Diseases and Sciences, 2016, 61, 1950-1960.	2.3	13

#	Article	IF	CITATIONS
19	Expressional and prognostic value of <scp>HPCAL1</scp> in cholangiocarcinoma via integrated bioinformatics analyses and experiments. Cancer Medicine, 0, , .	2.8	1